Azacitidine Mylan is used for the treatment of adults with the following diseases, if they cannot have haematopoietic stem cell transplantation (when the patient’s bone marrow is replaced to form new bone marrow that produces healthy cells):

• myelodysplastic syndromes, a group of conditions where the bone marrow produces abnormal blood cells and not enough healthy ones. In some cases, myelodysplastic syndromes can lead to acute myeloid leukaemia (AML, a cancer affecting white blood cells called myeloid cells). Azacitidine Mylan is used in patients with an intermediate to high risk of progressing to AML or death;
• chronic myelomonocytic leukaemia (a cancer affecting white blood cells called monocytes). Azacitidine Mylan is used when the bone marrow consists of 10 to 29% abnormal cells and the bone marrow is not producing large numbers of white blood cells;
• AML that has developed from a myelodysplastic syndrome, where the bone marrow consists of 20 to 30% abnormal cells;
• AML, where the bone marrow has more than 30% abnormal cells.

Azacitidine Mylan contains the active substance azacitidine.

Azacitidine Mylan is a ‘generic medicine’. This means that Azacitidine Mylan contains the same active substance and works in the same way as a ‘reference medicine’ already authorised in the EU called Vidaza. For more information on generic medicines, see the question-and-answer document here.